Stifel Nicolaus Downgrades Fulcrum Therapeutics (NASDAQ:FULC) to Hold

Fulcrum Therapeutics (NASDAQ:FULC) was downgraded by equities research analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a report released on Tuesday. They presently have a $3.00 price objective on the stock. Stifel Nicolaus’ target price would indicate a potential downside of 53.27% from the stock’s previous close.

A number of other equities research analysts have also issued reports on FULC. HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target on the stock. in a report on Tuesday. Piper Sandler lowered shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a report on Tuesday. Wall Street Zen raised shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Tuesday, April 21st. Finally, Leerink Partners reissued an “outperform” rating on shares of Fulcrum Therapeutics in a report on Tuesday, February 24th. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.20.

Fulcrum Therapeutics Stock Performance

Shares of Fulcrum Therapeutics stock opened at $6.42 on Tuesday. Fulcrum Therapeutics has a 52-week low of $5.88 and a 52-week high of $15.74. The stock has a market capitalization of $427.78 million, a price-to-earnings ratio of -5.58 and a beta of 3.02. The company’s 50 day moving average price is $7.23 and its 200-day moving average price is $9.22.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. As a group, equities research analysts forecast that Fulcrum Therapeutics will post -1.16 earnings per share for the current fiscal year.

Institutional Trading of Fulcrum Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new stake in shares of Fulcrum Therapeutics during the 1st quarter valued at $164,000. Jane Street Group LLC boosted its holdings in shares of Fulcrum Therapeutics by 62.1% during the 1st quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock valued at $339,000 after buying an additional 45,157 shares in the last quarter. Creative Planning bought a new stake in shares of Fulcrum Therapeutics during the 2nd quarter valued at $117,000. Legal & General Group Plc boosted its holdings in shares of Fulcrum Therapeutics by 230.2% during the 2nd quarter. Legal & General Group Plc now owns 17,461 shares of the company’s stock valued at $120,000 after buying an additional 12,173 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Fulcrum Therapeutics by 7.0% during the 2nd quarter. American Century Companies Inc. now owns 132,349 shares of the company’s stock valued at $911,000 after buying an additional 8,638 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.